Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat

Annals of Nutrition and Metabolism

Volumn 51, Issue 1, 2007, Pages 42-52

  Davis, Jeremy ^a   Higginbotham, Allan ^a   O'Connor, Timothy ^b   Moustaid Moussa, Naima ^c   Tebbe, Adam ^c   Kim, Young Cheul ^d   Cho, Kae Won ^e   Shay, Neil ^f   Adler, Stuart ^a   Peterson, Richard ^g   Banz, William ^a  

^a SOUTHERN ILLINOIS UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e PURDUE UNIVERSITY   (United States)

^f UNIVERSITY OF NOTRE DAME   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

Adiposity; Isoflavone content; Metabolic syndrome; Soy protein; Zucker Diabetic Fatty rats

Indexed keywords

CASEIN; FAS ANTIGEN; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; ISOFLAVONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SOYBEAN PROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GLYCEMIC CONTROL; IMMUNOBLOTTING; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY TUBULE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINURIA; RAT; STATISTICAL SIGNIFICANCE; ZUCKER DIABETIC FATTY RAT;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; CASEINS; HYPOGLYCEMIC AGENTS; ISOFLAVONES; KIDNEY DISEASES; LIVER; MALE; METABOLIC SYNDROME X; MILK PROTEINS; OBESITY; PROTEINURIA; RATS; RATS, INBRED STRAINS; SOYBEAN PROTEINS; THIAZOLIDINEDIONES;

ANIMALIA; RATTUS; RODENTIA;

EID: 34247339685     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100820     Document Type: Article

References (39)

1. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13-26.
2. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75:473-485.
3. Maher J: Antidiabetic treatment for NASH? Hepatology 2001;33:1338-1339.
4. Maddox DA, Alavi FK, Silbernick EM, Zawada ET: Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int 2002;61:96-104.
5. Smith SA, Lister CA, Toseland CDN, Buckingham RE: Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker Diabetic Fatty rat. Diabetes Obes Metab 2000;2:363-372.
6. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, et al: A novel n-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker Diabetic Fatty rat. Diabetes 1999;48:1415-1424.
7. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101: 1354-1351.
8. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
9. Scheen AJ: Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004;27:841-856.
10. Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305-313.
11. Cheng AY, Fantus IG: Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 2004;38:817-820.
12. Velasquez MT, Bhathena SJ: Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001;37:1056-1068.
13. Ranich T, Bhathena SJ, Velasquez MT: Protective effects of dietary phytoestrogens in chronic renal disease. J Ren Nutr 2001;11: 183-193.
14. Trujillo J, Ramirez V, Perez J, Torre-Villalvazo I, Torres N, Tovar AR, et al: Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am J Physiol Renal Physiol 2005; 288:F108-F116.
15. Fair DE, Ogborn MR, Weiler HA, Bankovic-Calic N, Nitschmann EP, Fitzpatrick-Wong SC, et al: Dietary soy protein attenuates renal disease progression after 1 and 3 weeks in Han:SPRD-cy weanling rats. J Nutr 2004; 134:1504-1507.
16. Nevala R, Vaskonen T, Vehniainen J, Korpela R, Vapaatalo H: Soy-based diet attenuates the development of hypertension when compared to casein-based diet in spontaneously hypertensive rat. Life Sci 2000;66:115-124.
17. Tovar-Palacio C, Potter SM, Hafermann JC, Shay NF: Intake of soy protein and soy protein extracts influence lipid metabolism and hepatic gene expression in gerbils. J Nutr 1998;128:839-842.
18. Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL: A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999; 159:2070-2076.
19. Fukui K, Tachibana N, Wanezaki S, Tsuzaki S, Takamatsu K, Yamamoto T, et al: Isoflavone-free soy protein prepared by column chromatography reduces plasma cholesterol in rats. J Agric Food Chem 2002;50:5717-5721.
20. Peluso MR, Winters TA, Shanahan MF, Banz WJ: A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr 2000;130: 2333-2342.
21. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003;133:1238-1243.
22. Davis J, Steinle J, Higginbotham DA, Oitker J, Peterson RG, Banz WJ: Soy protein influences insulin sensitivity and cardiovascular risk in male lean SHHF rats. Horm Metab Res 2005;37:309-315.
23. Davis J, Iqbal MJ, Steinle J, Oitker J, Higginbotham DA, Peterson RG, et al: Soy protein influences the development of the metabolic syndrome in male obese ZDFxSHHF rats. Horm Metab Res 2005;37:316-325.
24. Setchell KDR: Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998;68(suppl):1333S-1346S.
25. Iqbal MJ, Yaegashi S, Ahsan R, Lightfoot DA, Banz WJ: Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate. Physiol Genomics 2002; 11:219-226.
26. Peterson RG: The zucker diabetic fatty (ZDF) rat;in Sima AAF, Shafrir E (eds): Animal Models of Diabetes A Primer. The Netherlands, Harwood Academic Publishers, 2001, pp 109-128.
27. Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93-purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-1951.
28. Jones BH, Standridge M, Moustaid N: Angiotensin II increases lipogenesis in murine 3T3-L1 and human adipose cells. Endocrinology 1997;138:1512-1519.
29. Reaven GM: The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391-406.
30. Berg AH, Combs TP, Scherer PE: ACRP30/ adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-89.
31. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB: Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-4548.
32. Anderson JW, Johnstone BM: Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-282.
33. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
34. Tovar AR, Torre-Villalvazo I, Ochoa M, Elias AL, Ortiz V, Aguilar-Salinas CA, Torres N: Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005;46:1823-1832.
35. Boden G, Chen X, Rosner J, Barton M: Effects of a 48-hour fat infusion on insulin secretion and glucose utilization. Diabetes 1995;44:1239-1242.
36. Mogensen CE: Diabetic renal disease in patients with type 2 diabetes mellitus: new strategies for prevention and treatment. Treat Endocrinol 2002;1:3-11.
37. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-176.
38. Banz W, Hauck S, Gename B, Winters T, Bartke A: Soy isoflavones modify liver free radical scavenger systems and liver parameters in Sprague-Dawley rats. J Med Food 2004;7:477-481.
39. Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF: Dietary isoflavone supplementation modulates lipid metabolism via PPARα-dependent and independent mechanisms. Physiol Genomics 2006;26:8-14.